ANTIMICROBIAL RESISTANCE AS A DUAL CRISIS: EVOLUTIONARY BIOLOGY VERSUS GLOBAL HEALTH GOVERNANCE

Mujeeb ali

Medical Student, Samarkand state medical university, Uzbekistan

mrmujeebali2003@gmail.com

Mohd Sami

Medical Student, Samarkand state medical university, Uzbekistan

mohdsami63956@gmail.com

Mohammad Ayaz

Medical Student, Samarkand state medical university, Uzbekistan

Alimohdayaz74@gmail.com

Keywords: Antimicrobial resistance, horizontal gene transfer, global health governance, One Health, National Action Plans, mobile genetic elements, Quadripartite alliance, antibiotic stewardship, evolutionary biology, AMR surveillance

Abstract

Antimicrobial resistance (AMR) represents one of the most formidable challenges to modern medicine and public health, simultaneously operating as a crisis of biological evolution and a crisis of international governance. On the biological front, bacteria deploy sophisticated evolutionary mechanisms—including horizontal gene transfer, mobile genetic elements, and biofilm formation—to circumvent antimicrobial agents. On the governance front, the global community struggles with fragmented policy implementation, inadequate funding, and stark disparities across human, animal, and environmental health sectors. This article examines AMR through the lens of this dual crisis, exploring how evolutionary pressures drive resistance emergence while governance failures allow these biological threats to proliferate unchecked. Drawing upon the recently updated Global Action Plan on Antimicrobial Resistance (2026–2036) and recent epidemiological forecasts, we argue that bridging the gap between evolutionary understanding and policy execution is essential for preserving antimicrobial efficacy for future generations.

1. Introduction

The discovery of penicillin by Alexander Fleming in 1928 heralded a new era in medicine, transforming once-fatal bacterial infections into treatable conditions. Yet, less than a century later, humanity faces the prospect of a post-antibiotic era where routine surgeries, cancer chemotherapy, and minor infections could once again become life-threatening. Antimicrobial resistance was responsible for an estimated 4.71 million deaths worldwide in 2021, and without decisive intervention, annual mortality attributable to AMR is projected to rise to 8.22 million by 2050 . The economic consequences are equally staggering, with projected losses of up to 3.8% of global gross domestic product and an additional 28 million people pushed into extreme poverty .

What makes AMR uniquely challenging is its dual nature as both a biological phenomenon and a governance failure. From an evolutionary biology perspective, antimicrobial resistance is an inevitable consequence of natural selection operating on microbial populations under pharmacological pressure. Bacteria possess remarkable genetic plasticity, enabling them to acquire, accumulate, and disseminate resistance determinants across species boundaries through mechanisms that have evolved over billions of

years . Simultaneously, from a global health governance perspective, AMR represents a catastrophic market failure and a coordination problem of unprecedented scale. The development of new antibiotics has slowed to a crawl due to poor economic incentives, while existing drugs are misused and overused across human medicine, agriculture, and aquaculture.

The 68th World Health Assembly formally adopted the Global Action Plan (GAP) on Antimicrobial Resistance in 2015, calling upon all member states to develop National Action Plans (NAPs) grounded in a One Health approach . A decade later, the updated Global Action Plan (2026–2036) aims to achieve a 10% reduction in bacterial AMR-associated human deaths, reduce global antimicrobial use in agrifood systems, and minimize environmental pollution by 2030 . However, a critical question remains: Can governance mechanisms evolve as rapidly as the microbes they seek to control?

This article argues that understanding AMR requires simultaneous engagement with evolutionary biology and global health governance. We first examine the biological mechanisms driving resistance, then analyze the architecture and shortcomings of current governance frameworks, and finally propose integrative strategies that align evolutionary insights with policy implementation.

2. The Evolutionary Biology of Resistance: Nature's Defense Arsenal

2.1 Horizontal Gene Transfer and the Mobility of Resistance

The genetic evolution of antimicrobial resistance is orchestrated through a complex interplay of horizontal gene transfer (HGT) mechanisms, mobilization of resistance genes via mobile genetic elements (MGEs), and persistence of these determinants within environmental and clinical reservoirs . Unlike vertical inheritance, HGT allows bacteria to acquire resistance traits from unrelated species, dramatically accelerating the spread of multidrug resistance.

Bacteria acquire new resistance traits primarily through three HGT mechanisms. **Conjugation**, the direct transfer of plasmid DNA between bacteria via cell-to-cell contact, is the most efficient mode and is responsible for the dissemination of critical resistance genes such as *bla*CTX-M, *bla*NDM, and *bla*KPC . **Transformation**, the uptake of free DNA from the environment, facilitates resistance acquisition in naturally competent species such as *Streptococcus pneumoniae* and *Acinetobacter baumannii*. **Transduction**, mediated by bacteriophages, enables the transfer of resistance genes embedded within viral genomes, contributing to resistance spread in both clinical and environmental reservoirs .

2.2 Mobile Genetic Elements: The Vehicles of Resistance

The mobility of resistance genes is underpinned by MGEs, including plasmids, transposons, and integrons, which serve as vehicles for gene capture and dissemination . Plasmids—small, circular, self-replicating DNA molecules—frequently harbor clusters of resistance genes and facilitate their horizontal spread across bacterial species and genera. Transposons, or "jumping genes," can excise and integrate into different genomic locations, often carrying multiple resistance determinants such as *tet(M)* for tetracycline resistance and *vanA* for vancomycin resistance .

Integrons represent particularly concerning genetic platforms capable of capturing, incorporating, and expressing gene cassettes encoding antibiotic resistance. Class 1 integrons are widely associated with resistance to aminoglycosides, sulfonamides, and β-lactams and are frequently linked to transposons and plasmids, amplifying their impact on AMR dissemination . The assembly of these elements into multidrug-resistant loci means that a single genetic event can confer simultaneous resistance to multiple antibiotic classes.

2.3 Molecular Mechanisms of Evasion

At the molecular level, bacteria employ four principal strategies to evade antimicrobial agents :

Table 1: Principal Molecular Mechanisms of Antimicrobial Resistance

Mechanism	Description	Example Genes/Systems	Clinical Impact

Mechanism	Description	Example Genes/Systems	Clinical Impact
Enzymatic Inactivation	Production of enzymes that chemically modify or degrade antibiotics	β-lactamases, aminoglycoside-modifying enzymes	Renders β-lactams and aminoglycosides ineffective
Target Modification	Genetic mutations or post-translational alterations in antibiotic binding sites	*gyrA*, *parC* (fluoroquinolone resistance), altered PBPs	Reduces drug binding affinity
Active Efflux	Overexpression of membrane pumps that expel antibiotics from the cell	AcrAB-TolC (E. coli), MexAB-OprM (P. aeruginosa)	Contributes to multidrug resistance phenotypes
Reduced Permeability	Alterations or loss of outer membrane porins limiting drug entry	OprD loss (P. aeruginosa), OmpK36 mutations (K. pneumoniae)	Decreases intracellular drug concentrations

These mechanisms rarely operate in isolation. Genomic studies demonstrate that they frequently evolve concurrently, enhancing multidrug resistance and complicating clinical management . Furthermore, biofilm formation creates protective extracellular polymeric matrices that limit antibiotic penetration, while persister cells—non-mutant, non-proliferative phenotypic variants—remain dormant during antibiotic exposure, enabling the persistence of chronic infections .

2.4 The Evolutionary Arms Race

The relationship between antibiotics and bacteria exemplifies an evolutionary arms race. Every antibiotic deployment applies selective pressure that favors resistant subpopulations. The fitness cost historically associated with resistance mutations—where resistant bacteria grew more slowly than susceptible counterparts—has been mitigated through compensatory evolution. Modern resistant strains often exhibit minimal fitness deficits, allowing them to thrive in both clinical and community settings even in the absence of antibiotic pressure.




Figure 1 — The Dual Crisis of Antimicrobial Resistance]

Figure 1. (Left) Projected AMR-attributable deaths worldwide from 2021 to 2050, demonstrating an upward trajectory from 4.71 million to 8.22 million deaths annually. (Right) AMR governance scores by sector in 2022, revealing significant disparities between human health (56.1), animal health (45.5), and environmental health (18.3) sectors. Data synthesized from the Global Burden of Disease Study and Nature Medicine governance evaluation.

3. Global Health Governance: From Declarations to Implementation

3.1 The Architecture of AMR Governance

The global response to AMR has evolved considerably since 2015. Political momentum has grown following the 2016 and 2024 United Nations General Assembly high-level meetings, successive G7 and G20 commitments, and biennial ministerial conferences . Global governance structures now include the Quadripartite Joint Secretariat on AMR, the Global Leaders Group on AMR, the AMR Multi-Stakeholder Partnership Platform, and the Independent Panel on Evidence for Action against AMR .

The Quadripartite alliance—comprising the World Health Organization (WHO), the Food and Agriculture Organization (FAO), the World Organisation for Animal Health (WOAH), and the United Nations Environment Programme (UNEP)—represents a landmark expansion of AMR governance . The inclusion of UNEP in 2021 elevated the environmental dimension of AMR to parity with human and animal health priorities, acknowledging that resistant microbes and antimicrobial residues circulate through water, soil, and food systems.

Over 170 countries have developed multisectoral AMR national action plans, and surveillance capacity has strengthened across sectors . In 2025, 104 countries reported antimicrobial use data to the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS), while antimicrobial use in animals decreased by 5% globally between 2020 and 2022 .

3.2 The Implementation Gap

Despite these advances, a substantial implementation gap persists. Although 178 countries have established NAPs, only 68% are currently being implemented, and merely 11% have dedicated funding . This disparity between policy design and execution represents the central governance crisis of AMR.

A comprehensive evaluation of AMR governance across 193 countries revealed that while policy design and monitoring improved between 2017 and 2022, the implementation domain progressed significantly more slowly . In 2022, the global average AMR governance score was 44.5 out of 100, with considerable variation across countries and regions .

Table 2: Regional Variation in National Action Plan Adoption and Governance (2022)

WHO Region	NAP Adoption Rate	Avg. Governance Score	Key Challenges
South-East Asia (SEARO)	100% (11/11)	Moderate	High resistance prevalence, variable implementation
Eastern Mediterranean (EMRO)	100% (21/21)	Low-Moderate	Limited surveillance infrastructure
European (EURO)	81% (43/53)	High	Eastern sub-region disparities
Western Pacific (WPRO)	85% (23/27)	Moderate	Heterogeneous health systems
African (AFRO)	74% (35/47)	Low	Funding constraints, laboratory

WHO Region	NAP Adoption Rate	Avg. Governance Score	Key Challenges
			capacity gaps
Americas (AMRO)	43% (15/35)	Moderate	Lowest adoption rate globally

Adapted from Nature Medicine evaluation of global AMR governance

3.3 Sectoral Disparities and the Environmental Blind Spot

AMR governance scores reveal stark sectoral disparities. The human health sector scored highest (mean 56.1), followed by animal health (45.5), while the environmental sector lagged dramatically at 18.3 . This environmental blind spot is particularly concerning given the role of wastewater, agricultural runoff, and pharmaceutical manufacturing waste in disseminating resistance genes.

The updated Global Action Plan (2026–2036) explicitly addresses these gaps by mandating strengthened regulatory frameworks across the full antimicrobial life cycle—from development and manufacturing to distribution, use, and disposal . Key provisions include phasing out the use of antimicrobials for growth promotion, curtailing over-the-counter and unregulated online sales, and implementing extended producer responsibility for pharmaceutical waste .

3.4 Surveillance and the Evidence Gap

Effective governance requires robust evidence, yet significant surveillance gaps persist. While 104 countries report to GLASS and over 50 use the FAO's InFARM system, environmental monitoring of resistant microbes and antimicrobial residues remains limited . The Quadripartite organizations are developing the Global Integrated Surveillance System on AMR as a cross-sectoral data repository, but capacity building in low-resource settings remains a formidable barrier.

Research published in 2026 demonstrated that among governance subdomains, multisector engagement and antimicrobial use surveillance systems were the strongest positive predictors of improvements in AMR prevalence . Countries that achieved the greatest gains in reducing resistance maintained robust cross-sectoral coordination and systematic monitoring of antibiotic consumption.

4. The Collision: Where Evolution Outpaces Governance

4.1 The Mismatch Between Biological and Policy Timescales

The central tension in the AMR crisis lies in the mismatch between biological and political timescales. Bacteria can acquire and disseminate resistance genes within hours through conjugation, while governance mechanisms require years of negotiation, ratification, and implementation. A novel resistance mechanism emerging in a hospital in Delhi can spread globally via medical tourism and food trade before policymakers convene their next meeting.

This temporal asymmetry is compounded by the failure of market incentives. The pharmaceutical industry has largely abandoned antibiotic research and development because novel agents are held in reserve for last-resort use, limiting commercial returns. The IFPMA Biopharmaceuticals CEO Roundtable AMR Action Fund represents one industry-led effort to address this pipeline crisis, but sustainable models for antibiotic development remain elusive .

4.2 The One Health Paradox

The One Health framework—which recognizes the interconnectedness of human, animal, and environmental health—has become the dominant paradigm for AMR governance. Yet, its implementation reveals a paradox: while the framework acknowledges systemic interconnectedness, governance structures remain siloed. Human health ministries, veterinary services, and environmental agencies often operate with separate budgets, reporting mechanisms, and regulatory authorities.

The updated Global Action Plan explicitly calls for coordination between human, veterinary, and environmental regulatory authorities, emphasizing that accountability mechanisms must transcend traditional sectoral boundaries . However, achieving this integration requires not merely policy coordination but fundamental restructuring of institutional incentives and resource allocation.

4.3 Access Versus Excess: The Equity Dimension

AMR governance must navigate the treacherous terrain between access and excess. In many low- and middle-income countries, the problem is not overuse but lack of access to essential antibiotics, resulting in preventable deaths from treatable infections. Conversely, in high-income settings and industrial agriculture, excessive and inappropriate use drives resistance selection.

The updated Global Action Plan emphasizes equitable accessibility of safe and effective antimicrobials for current and future generations . This dual commitment—to reduce inappropriate use while ensuring universal access—requires differentiated governance strategies that account for disparate epidemiological and economic contexts.

5. Toward Evolutionarily Informed Governance

5.1 Integrating Evolutionary Principles into Policy

Effective AMR governance must incorporate evolutionary principles into policy design. This includes:

Antibiotic Stewardship Based on Resistance Dynamics: Treatment guidelines should account for the evolutionary fitness costs and compensatory mutations associated with specific resistance mechanisms. Cycling strategies, combination therapies, and dose optimization can be designed to minimize selective pressure while maximizing clinical efficacy.

Surveillance of Mobile Genetic Elements: Beyond tracking phenotypic resistance, surveillance systems must monitor the circulation of plasmids, integrons, and transposons in environmental and clinical reservoirs. Genomic surveillance offers unprecedented resolution for tracking resistance gene flow across sectors and borders.

Environmental Resistance Management: Recognizing that environmental reservoirs serve as incubators for resistance, governance must prioritize wastewater treatment, pharmaceutical manufacturing standards, and agricultural runoff controls. The environmental sector's current governance score of 18.3 represents an unacceptable vulnerability .

5.2 Strengthening Implementation Mechanisms

To bridge the implementation gap, the international community must move from voluntary commitments to binding obligations with dedicated financing. The AMR Multi-Partner Trust Fund, established in 2019, provides a mechanism for channeling resources to national programs, but current funding levels are insufficient for the scale of the challenge .

The 2024 UN General Assembly political declaration comprising 106 commitments and the 4th Global High-Level Ministerial Conference's emphasis on shifting "from declarations to implementation" represent important rhetorical advances . However, without enforceable compliance mechanisms and transparent reporting through instruments such as the Tracking AMR Country Self-Assessment Survey (TrACSS), these commitments risk remaining aspirational.

5.3 Innovation and Alternative Therapeutics

Governance frameworks must actively support innovation beyond traditional antibiotics. This includes phage therapy, CRISPR-based antimicrobial strategies, monoclonal antibodies, and vaccines that prevent infections and thereby reduce antibiotic demand. The updated Global Action Plan prioritizes research and innovation as a strategic objective, but realizing this ambition requires addressing the market failures that have stifled antibiotic development .

Table 3: Strategic Objectives of the Updated Global Action Plan on AMR (2026–2036)

Strategic Objective	Target Outcome	Key Interventions
Improve awareness and education	Behavioral change across sectors	Public awareness campaigns, professional training
Strengthen surveillance and research	Evidence-based policy	Integrated surveillance, genomic monitoring
Reduce incidence of infection	10% reduction in AMR deaths	Vaccination, WASH programs, infection prevention
Optimize antimicrobial use	Reduced global AMU in agrifood	Diagnostic stewardship, regulatory harmonization
Ensure sustainable investment	Dedicated funding for NAPs	Multi-Partner Trust Fund, innovative financing
Promote access and innovation	Equitable availability of medicines	R&D incentives, technology transfer, local production

Synthesized from WHO Executive Board Document EB158/18

6. Conclusion

Antimicrobial resistance stands as a defining crisis of the twenty-first century, simultaneously revealing the awesome power of microbial evolution and the frailty of human institutions. The biological dimension of this crisis is characterized by the remarkable genetic adaptability of bacteria, whose horizontal gene transfer mechanisms, mobile genetic elements, and molecular evasion strategies operate with a speed and sophistication that outpaces traditional policy responses. The governance dimension is marked by ambitious frameworks—most notably the Global Action Plan on Antimicrobial Resistance and its 2026–2036 update—that struggle with implementation deficits, sectoral fragmentation, and chronic underfunding.

The dual nature of AMR demands an integrated response that treats evolutionary biology and global health governance not as separate domains but as inseparable facets of a single challenge. Governance mechanisms must be designed with evolutionary principles in mind: antibiotic stewardship should minimize selective pressure, surveillance should track genetic elements as well as phenotypes, and environmental controls should address the reservoirs where resistance genes accumulate and disseminate.

The updated Global Action Plan's targets—a 10% reduction in bacterial AMR-associated deaths, reduced antimicrobial use in agrifood systems, and minimized environmental pollution by 2030—are ambitious but achievable if the implementation gap is closed . Achieving these goals requires moving beyond the comfort of declarations into the difficult work of institutional reform, sustainable financing, and cross-sectoral coordination.

As the projected death toll rises toward 8.22 million annually by 2050, the question is not whether microbes will continue to evolve—they will—but whether human governance can evolve equally rapidly. The survival of antimicrobial medicine depends upon the answer.

References

1. World Health Organization. *Draft Updated Global Action Plan on Antimicrobial Resistance*. Executive Board 158th Session, Document EB158/18. Geneva: WHO; 2026.
2. Naghavi M, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet*. 2024;404:1199–1226.
3. PMC. Mechanisms of antimicrobial resistance: From genetic evolution to molecular strategies. *PMC*. 2025;12782932.

4. International Federation of Pharmaceutical Manufacturers Associations (IFPMA). Statement on Draft Updated Global Action Plan on Antimicrobial Resistance at the 158th Session of the WHO Executive Board. Geneva: IFPMA; 2026.

5. Musicha P, et al. Time to define One Health approaches to tackling antimicrobial resistance. *Nature Communications*. 2024;15:8782.

6. Patel J, et al. Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories. *The Lancet Infectious Diseases*. 2025;26:55–66.

7. World Bank. *Antimicrobial Resistance (AMR): Economic Impact Brief*. Washington, DC: World Bank; 2025.

8. United Nations. *Political Declaration of the High-level Meeting on Antimicrobial Resistance*. New York: UN; 2024.

9. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? *Nature Reviews Microbiology*. 2010;8:260–271.

10. Charani E, et al. An analysis of existing national action plans for antimicrobial resistance—gaps and opportunities. *The Lancet Global Health*. 2023;11:e466–e474.